News
AXNX
66.64
+0.26%
0.17
BOSTON SCIENTIFIC CORP- SEES NET SALES GROWTH FOR Q2 OF 2024, TO BE IN A RANGE OF ABOUT 10 TO 12 PERCENT ON AN ORGANIC BASIS
Reuters · 1d ago
BOSTON SCIENTIFIC CORP- SEES Q2 EPS ON A GAAP BASIS IN A RANGE OF $0.35 TO $0.37 AND ADJUSTED EPS, OF $0.57 TO $0.59
Reuters · 1d ago
Press Release: Boston Scientific Announces -4-
Earnings per Share is a measure of Boston Scientific's performance. The company expects to report earnings per share for the year ending September 30, 2024. The company does not expect to release a full year 2024 earnings estimate until after the end of the year. The Company's results are calculated on a GAAP basis.
Dow Jones · 1d ago
Press Release: Boston Scientific Announces Results for First Quarter 2024
Boston Scientific Corporation generated net sales of $3.856 billion during the first quarter of 2024. The company reported GAAP net income attributable to Boston Scientific common stockholders of $495 million. First quarter sales grew 13.8 percent on a reported basis and 13.1 percent on an organic basis. The initial U.S. Launch of the FARAPULSE(TM) Pulsed Field Ablation System.
Dow Jones · 1d ago
Wells Fargo Sticks to Its Hold Rating for Axonics Modulation Technologies (AXNX)
TipRanks · 1d ago
Weekly Report: what happened at AXNX last week (0415-0419)?
Weekly Report · 3d ago
FDA Classifies Boston Scientific's Recall For Device To Stop Blood Flow As 'Most Serious'
Boston Scientific Corporation said it recalled Obsidio Embolic by issuing a correction. The FDA has identified this as a Class I recall, the most severe type of recall. Eleven incidents were reported, seven injuries, and two deaths related to this issue. The company has issued a recall for around 1,600 devices.
Benzinga · 6d ago
RBC Capital Remains a Hold on Axonics Modulation Technologies (AXNX)
TipRanks · 04/17 08:00
Weekly Report: what happened at AXNX last week (0408-0412)?
Weekly Report · 04/15 09:14
RBC Capital Sticks to Its Hold Rating for Axonics Modulation Technologies (AXNX)
TipRanks · 04/11 01:45
Weekly Report: what happened at AXNX last week (0401-0405)?
Weekly Report · 04/08 09:15
Boston Scientific: Implications Of The Axonics-Medtronic Patent Clash
Boston Scientific expects 8-10% sales growth in their 2024-2026 guidance. Boston Scientific's share price has risen 17.79% year to date. The legal clash between Axonics and Medtronic may endanger the company's ability to commercialize Axonics' products in the near future. The company is currently trading at historically high prices and is overvalued.
Seeking Alpha · 04/05 10:42
Noteworthy Thursday Option Activity: AXNX, ABBV, ROKU
NASDAQ · 04/04 21:21
BUZZ-U.S. STOCKS ON THE MOVE-US banks, Hertz, Spirit,
Wall Street's main stock indexes advanced on Thursday. The Dow Jones Industrial Average was up 0.39% at 39,279.3. The top three S&P 500 percentage gainers were Enphase Energy, Delta Air Lines. The Nasdaq Composite was up 1.06%.
Reuters · 04/04 18:02
BUZZ-U.S. STOCKS ON THE MOVE-Delta Air Lines, Alternus Clean Energy, US banks
Wall Street's main stock indexes advanced on Thursday. Dow Jones Industrial Average was up 0.41% at 39,288.94. Delta Air Lines and Alternus Clean Energy were among the biggest decliners on the New York Stock Exchange. The Nasdaq composite and S&P 500 were both up.
Reuters · 04/04 15:52
BUZZ-U.S. STOCKS ON THE MOVE-Meta, Intuitive Machines, Conagra Brands
Dow e-minis set for a higher open on Thursday. Recent economic reports boosted prospect of monetary policy easing later this year. Meta Platforms, Intuitive Machines, Conagra Brands and BlackBerry among top stocks on the move. The top three NYSE percentage gainers premarket were Allurion Technologies, Levi Strauss and BlackBerry.
Reuters · 04/04 13:25
BUZZ-Axonics falls as FTC seeks information on buyout offer from Boston Scientific
U.S. FTC seeks information on buyout offer from Boston Scientific. Shares of medtech co Axonics fall 3.2% to $67.50 premarket. FTC has requested additional information from co on Boston Scientific's BSX.N $3.7 billion buyout deal.
Reuters · 04/04 12:19
Boston Scientific/Axonics merger to close in 2H24 as FTC seeks more info
Healthcare M&A Boston Scientific/Axonics merger to close in 2H24 as FTC seeks more info. Boston Scientific agreed to acquire the med-tech firm for $71 per share in cash in January. The companies received a request from the FTC for additional information pertaining to the deal.
Seeking Alpha · 04/04 12:09
UPDATE 1-FTC seeks more information on Boston Scientific's $3.7 bln Axonics deal
FTC seeks more information on Boston Scientific's $3.7 bln deal to buy Axonics. Medical device maker expects the deal to be completed in the second half of 2024. Boston Scientific says Axonics has also received a request for additional information from the FTC.
Reuters · 04/04 11:45
Weekly Report: what happened at AXNX last week (0325-0329)?
Weekly Report · 04/01 09:15
More
Webull provides a variety of real-time AXNX stock news. You can receive the latest news about Axonics Inc through multiple platforms. This information may help you make smarter investment decisions.
About AXNX
Axonics, Inc. is a medical technology company, which develops and commercializes products to treat adults with bladder and bowel dysfunction. The Company has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10cc in volume, utilizes constant current stimulation, an easy-to-use, intuitive recharge-free patient remote control and other related accessories. It engineered its recharge-free sacral neuromodulation (SNM) system to deliver constant-current stimulation. Its SNM system includes an easy-to-use wireless patient remote control that does not require recharging or replacement batteries.